What ails Big PharmaA new book chronicles the uneasy relationship between money and drugs, and what it means for the rest of us.
Ranbaxy’s empty promisesThe big manufacturer of generic drugs—including a non-branded version of Lipitor—has landed in trouble again, and once again it is promising to clean up its act. Should anybody believe the company?
Painful prescriptionPharmacy benefit managers became a $250 billion industry by promising to save companies millions on employee medications. But critics say they make out better than their customers.
Why the Supreme Court is wrong on generic drugsIts latest decision is based on a faulty premise.
The latest to claim fraud at generic Lipitor maker Ranbaxy: Its ownersJapanese drugmaker Daiichi Sankyo has quietly stood by its decision to purchase Ranbaxy in 2008. Now, though, the company is publicly suggesting it was defrauded in the $4.6 billion acquisition.
Dirty medicineThe epic inside story of long-term criminal fraud at Ranbaxy, the Indian drug company that makes generic Lipitor for millions of Americans.
Maker of generic Lipitor pleads guilty to selling ‘adulterated drugs’Ranbaxy Laboratories pleads guilty to seven criminal counts.
Skip to Content
